Alkermes buys back $18 million more of its 7% secured notes due 2012

New York, May 28 - Alkermes, Inc. said it bought back a further $18 million of its 7% non-recourse Risperdal Consta secured notes due Jan. 1, 2012 during the fourth fiscal quarter ended March 31.

The company paid $17.6 million for the securities in two separate transactions.

During the year ended March 31, Alkermes bought back $93 million principal amount of the notes for $89.4 million, according to a 10-K filing with the Securities and Exchange Commission.

That was up from $75 million of the notes repurchased in three separate transactions in June and July 2008 for $71.8 million, as reported in the 10-Q filing for the quarter ended Dec. 31, 2008.

Following the latest buybacks, Alkermes has $77 million of the notes outstanding.

Alkermes is a Cambridge, Mass., pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.